Fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Intervention not reported
Total number of adverse events · children with chronic asthma
The intervention showed no clear difference in total number of adverse events (high certainty).
1 finding from 1 review
Intervention not reported
Total number of adverse events · children with chronic asthma
The intervention showed no clear difference in total number of adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
1 finding from 1 review
Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis
LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (high certainty).
1 finding from 1 review
Anxiety (adverse effect, post‐intervention) · adults (aged 16 years and over) with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · children with chronic asthma
Children: formoterol/fluticasone showed no clear difference in all‐cause non‐fatal serious adverse events compared with salmeterol/fluticasone (low certainty).
1 finding from 1 review